Home › Diffuse Large B-Cell Lymphoma › District of Columbia
Diffuse Large B-Cell Lymphoma clinical trials in District of Columbia
4 studies for Diffuse Large B-Cell Lymphoma are looking for participants at sites in District of Columbia.
Cities in District of Columbia
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- MedStar Georgetown University Hospital, Washington D.C.
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06500273A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- Georgetown University Medical Center ( Site 0117), Washington D.C.
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06890884Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Medstar Georgetown University Hospital, Washington D.C.
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 25, 2026 · NCT05826535A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- MedStar Georgetown University Hospital, Washington D.C.
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 4, 2026 · NCT07188558From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.